Diamond S, Rakestraw D, O'Neil J, Lam G N, Christ D D
Section of The Du Pont Merck Pharmaceutical Company, Stine-Haskell Research Center, Newark, DE 19714.
Drug Metab Dispos. 1994 Jan-Feb;22(1):65-73.
The effects of the novel cognitive enhancer linopirdine [3,3-bis(4-pyridinylmethyl)-1-phenylindolin-2-one] on hepatic cytochromes P-450 (CYP) and linopirdine metabolism were determined in female mice fed 0, 10, 50, and 250 mg/kg/day of linopirdine in the diet for 4, 7, 14, and 28 days. Linopirdine induced CYP maximally by day 4 only at the highest dose, as demonstrated by significant (p < 0.05) increases in total spectral CYP and liver weight. SDS-PAGE revealed induced 52 kDa microsomal protein(s), identified as CYP2B and 3A by immunoblotting. Linopirdine also increased the rates of reactions selectively catalyzed by CYP2B and 3A (pentoxyresorufin O-dealkylation, benzphetamine N-demethylation, erythromycin N-demethylation, and testosterone 2 beta-, 6 beta-, 16 beta-hydroxylation), 1.7- to 3.0-fold vs. control, similar to increases produced by the prototypical CYP2B and 3A inducers phenobarbital and dexamethasone. No increase in microsomal CYP1A or 2E levels was demonstrated by immunoblotting or selective substrate assays. CYP induction increased the metabolism of linopirdine. The area under the plasma concentration-time curve of linopirdine after a 250 mg/kg/day dose decreased 11-fold from day 1-28, and microsomes from a parallel 250 mg/kg/day group metabolized linopirdine 1.9-fold faster than control (p < 0.05). This autoinduction was due primarily to the induced CYP3A, because antibodies recognizing CYP3A inhibited the microsomal metabolism of linopirdine by 85%, whereas antibodies to CYP2B were not inhibitory. In summary, the dietary consumption of 250 mg/kg/day of linopirdine by female mice coinduced CYP2B and 3A maximally by day 4, and resulted in an increased rate of metabolism of linopirdine, predominantly due to CYP3A.
在饮食中分别给予雌性小鼠0、10、50和250mg/kg/天的新型认知增强剂利诺吡啶[3,3 - 双(4 - 吡啶基甲基)-1 - 苯基吲哚啉 - 2 - 酮],持续4、7、14和28天,测定其对肝细胞色素P - 450(CYP)和利诺吡啶代谢的影响。仅在第4天,最高剂量的利诺吡啶使CYP达到最大诱导,总光谱CYP和肝脏重量显著增加(p < 0.05)。SDS - PAGE显示诱导出52kDa的微粒体蛋白,通过免疫印迹鉴定为CYP2B和3A。利诺吡啶还使CYP2B和3A选择性催化的反应速率增加(戊氧基试卤灵O - 脱烷基化、苄非他明N - 去甲基化、红霉素N - 去甲基化以及睾酮2β -、6β -、16β - 羟基化),与对照组相比增加了1.7至3.0倍,类似于典型的CYP2B和3A诱导剂苯巴比妥和地塞米松所产生的增加。免疫印迹或选择性底物测定未显示微粒体CYP1A或2E水平增加。CYP诱导增加了利诺吡啶的代谢。250mg/kg/天剂量的利诺吡啶给药后,血浆浓度 - 时间曲线下面积从第1天到第28天下降了11倍,并且来自平行的250mg/kg/天组的微粒体代谢利诺吡啶的速度比对照组快1.9倍(p < 0.05)。这种自身诱导主要归因于诱导的CYP3A,因为识别CYP3A的抗体抑制利诺吡啶的微粒体代谢达85%,而针对CYP2B的抗体则无抑制作用。总之,雌性小鼠饮食中摄入250mg/kg/天的利诺吡啶在第4天最大程度地共同诱导CYP2B和3A,并导致利诺吡啶代谢速率增加,主要归因于CYP3A。